Andrew Smith

Is Nymox The Next Unknown Biotech Turned High Flyer?

The healthcare sector has significantly outperformed the broader markets over the last two years. Stock appreciation in the industry has occurred as investors reprice healthcare companies in response to an improving economy and in anticipation of the Patient Protection and Affordable Care Act (PPACA). Investors have not treated all healthcare subsectors equally however. Biotechnology pharmaceutical companies have been viewed as a winner as a result of additional individuals with health insurance or government paid care. The Office of the Actuary in the Centers for Medicare and Medicaid Services said the following in its 2012 national health expenditure report:

Because the newly insured populations are anticipated to be relatively younger and healthier than currently insured individuals they are expected to...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details